News
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...
The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app
